Related references
Note: Only part of the references are listed.Rituximab and Subcutaneous 2-Chloro-2′-Deoxyadenosine Combination Treatment for Patients With Waldenstrom Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study
Daniele Laszlo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Rituximab-Associated Neutropenia
Kieron Dunleavy et al.
SEMINARS IN HEMATOLOGY (2010)
Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia
Steven P. Treon et al.
BLOOD (2009)
High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom's macroglobulinemia
T. Caravita et al.
BONE MARROW TRANSPLANTATION (2009)
Lenalidomide and Rituximab in Waidenstrom's Macroglobulinemia
Steven P. Treon et al.
CLINICAL CANCER RESEARCH (2009)
Update on Treatment Recommendations From the Fourth International Workshop on Waldenstrom's Macroglobulinemia
Meletios Athanasios Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia
Kenneth A. Foon et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenstrom Macroglobulinemia Treated With Nucleoside Analogs
Xavier Leleu et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)
C. Buske et al.
LEUKEMIA (2009)
Comparative Outcomes Following CP-R, CVP-R, and CHOP-R in Waldenstrom's Macroglobulinemia
Leukothea Ioakimidis et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Thalidomide and rituximab in Waldenstrom macroglobulinemia
Steven P. Treon et al.
BLOOD (2008)
Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide
Meletios Athanasios Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma
Stefano Sacchi et al.
CANCER (2007)
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia
Eva Kimby et al.
CLINICAL LYMPHOMA & MYELOMA (2006)
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma
Constantine S. Tam et al.
CANCER (2006)
Fludarabine plus cyclophosphamide in Waldenstrom's macroglobulinemia:: results in 49 patients
J Tamburini et al.
LEUKEMIA (2005)
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
W Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
CHOP plus Rituximab therapy in Waldenstrom's macroglobulinemia
SP Treon et al.
CLINICAL LYMPHOMA (2005)
Extended rituximab therapy in Waldenstrom's macroglobulinemia
SP Treon et al.
ANNALS OF ONCOLOGY (2005)
Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): An eastern cooperative oncology group study (E3A98)
MA Gertz et al.
LEUKEMIA & LYMPHOMA (2004)
2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia
DM Weber et al.
SEMINARS IN ONCOLOGY (2003)
Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
RG Owen et al.
SEMINARS IN ONCOLOGY (2003)
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia:: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
RA Kyle et al.
SEMINARS IN ONCOLOGY (2003)
Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: An update of a US intergroup trial (SW0G S9003)
MV Dhodapkar et al.
SEMINARS IN ONCOLOGY (2003)
Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide
MA Dimopoulos et al.
LEUKEMIA & LYMPHOMA (2003)
Treatment of Waldenstrom's macroglobulinemia with rituximab
MA Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease
V Leblond et al.
BLOOD (2001)
Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the, cytotoxic activity of either drug alone
N Di Gaetano et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)
MV Dhodapkar et al.
BLOOD (2001)
CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia
SP Treon et al.
JOURNAL OF IMMUNOTHERAPY (2001)
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
JM Foran et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
